Abstract
An update of the guidelines for the management of dyslipidaemia was released in 2019. First, this is needed to assess cardiovascular risk and to classify the patient into one of four cardiovascular risk groups. The class of recommendations for using of imaging techniques and assessment of lipids and lipoproteins (including apolipoprotein B and apolipoprotein A) in the assessment of global cardiovascular risk has been strengthened. Values of LDL cholesterol were significantly reduced for each of risk group. The role of ezetimibe and PCSK9 inhibitors was strengthened, and the role of combination therapy in the treatment of dyslipidaemia was increased.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
